Skip to main content
Top
Published in: Medical Microbiology and Immunology 5/2019

01-10-2019 | Human Immunodeficiency Virus | Original Investigation

Discrimination between recent and non-recent HIV infections using routine diagnostic serological assays

Authors: Jaythoon Hassan, Joanne Moran, Gary Murphy, Olivia Mason, Jeff Connell, Cillian De Gascun

Published in: Medical Microbiology and Immunology | Issue 5/2019

Login to get access

Abstract

The suitability of routine diagnostic HIV assays to accurately discriminate between recent and non-recent HIV infections has not been fully investigated. The aim of this study was to compare an established HIV recency assay, the Sedia limiting antigen HIV avidity assay (LAg), with the diagnostic assays; Abbott ARCHITECT HIV Ag/Ab Combo and INNO-LIA HIV line assays. Samples from all new HIV diagnoses in Ireland from January to December 2016 (n = 455) were tested. An extended logistic regression model, the Spiegelhalter–Knill–Jones method, was utilised to establish a scoring system to predict recency of HIV infection. As proof of concept, 50 well-characterised samples were obtained from the CEPHIA repository whose stage of infection was blinded to the authors, which were tested and analysed. The proportion of samples that were determined as recent was 18.1% for LAg, 6.4% with the ARCHITECT, and 14.5% in the INNO-LIA assay. There was a significant correlation between the ARCHITECT S/CO values and the LAg results, r = 0.717, p < 0.001. ROC analysis revealed that an ARCHITECT S/CO < 250 had a sensitivity and specificity of 90.32% and 89.83%, respectively. Combining the Abbott ARCHITECT HIV Ag/Ab Combo assay and INNO-LIA HIV assays resulted in an observed risk of being recent of 100%. Analysis of the CEPHIA samples revealed a strong agreement between the LAg assay and the combination of routine assays (κ = 0.908, p < 0.001). Our findings provide evidence that assays routinely employed to diagnose and confirm HIV infection may be utilised to determine the recency of HIV infection.
Appendix
Available only for authorised users
Literature
2.
go back to reference Schüpbach J, Gebhardt MD, Tomasik Z et al (2007) Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med 4(12):e343CrossRefPubMedPubMedCentral Schüpbach J, Gebhardt MD, Tomasik Z et al (2007) Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med 4(12):e343CrossRefPubMedPubMedCentral
4.
go back to reference Schupbach J, Bisset LR, Regenass S et al (2011) High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease. BMC Infect Dis 11:254CrossRefPubMedPubMedCentral Schupbach J, Bisset LR, Regenass S et al (2011) High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease. BMC Infect Dis 11:254CrossRefPubMedPubMedCentral
5.
go back to reference Schupbach J, Bisset LR, Gebhardt MD et al (2012) Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. BMC Infect Dis 12:88CrossRefPubMedPubMedCentral Schupbach J, Bisset LR, Gebhardt MD et al (2012) Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. BMC Infect Dis 12:88CrossRefPubMedPubMedCentral
7.
go back to reference Wei X, Liu X, Dobbs T, Kuehl et al (2010) Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retrovirus 26:1–11CrossRef Wei X, Liu X, Dobbs T, Kuehl et al (2010) Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retrovirus 26:1–11CrossRef
8.
go back to reference Duong YT, Qiu M, De AK et al (2012) Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 7:e33328CrossRefPubMedPubMedCentral Duong YT, Qiu M, De AK et al (2012) Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 7:e33328CrossRefPubMedPubMedCentral
9.
go back to reference Parekh B, Duong Y, Mavengere Y et al (2012) Performance of new LAg-Avidity EIA to measure HIV-1 incidence in a cross-sectional population: Swaziland HIV Incidence Measurement Survey (SHIMS). In: XIX international AIDS conference. Washington DC. July 22–27, Abstract #LBPE27 Parekh B, Duong Y, Mavengere Y et al (2012) Performance of new LAg-Avidity EIA to measure HIV-1 incidence in a cross-sectional population: Swaziland HIV Incidence Measurement Survey (SHIMS). In: XIX international AIDS conference. Washington DC. July 22–27, Abstract #LBPE27
10.
go back to reference Schwarcz S, Kellogg T, McFarland W et al (2001) Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989–1998: application of the serological testing algorithm for recent HIV seroconversion. Am J Epidemiol 153:925–934CrossRefPubMed Schwarcz S, Kellogg T, McFarland W et al (2001) Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989–1998: application of the serological testing algorithm for recent HIV seroconversion. Am J Epidemiol 153:925–934CrossRefPubMed
11.
go back to reference Machado DM, Delwart EL, Diza RS et al (2002) Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 recently infected blood donors. AIDS 16:113–119CrossRefPubMed Machado DM, Delwart EL, Diza RS et al (2002) Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 recently infected blood donors. AIDS 16:113–119CrossRefPubMed
13.
go back to reference Seymour DG, Green M, Vaz FG (1990) Making better decisions: construction of clinical scoring systems by the Spiegelhalter–Knill–Jones approach. BMJ 300:223–226CrossRefPubMedPubMedCentral Seymour DG, Green M, Vaz FG (1990) Making better decisions: construction of clinical scoring systems by the Spiegelhalter–Knill–Jones approach. BMJ 300:223–226CrossRefPubMedPubMedCentral
14.
go back to reference Chan SF, Deeks JJ, Macaskill P, Irwig L (2008) Three methods to construct predictive models using logistic regression and likelihood ratios to facilitate adjustment for pretest probability give similar results. J Clin Epidemiol 1:52–63CrossRef Chan SF, Deeks JJ, Macaskill P, Irwig L (2008) Three methods to construct predictive models using logistic regression and likelihood ratios to facilitate adjustment for pretest probability give similar results. J Clin Epidemiol 1:52–63CrossRef
15.
go back to reference Suligoi B, Rodella A, Raimondo M et al (2011) Avidity index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Micro 49:2610–2613CrossRef Suligoi B, Rodella A, Raimondo M et al (2011) Avidity index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Micro 49:2610–2613CrossRef
16.
go back to reference Glese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, Ennis O, O’Donnell K, Keenan E, De Gascun C, Lyons F, Ward M, Danis K, Glynn R, Waters A, Fitzgerald M, On behalf of the outbreak control team (2015). Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland. Eurosurveillance 20(40):30036CrossRef Glese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, Ennis O, O’Donnell K, Keenan E, De Gascun C, Lyons F, Ward M, Danis K, Glynn R, Waters A, Fitzgerald M, On behalf of the outbreak control team (2015). Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland. Eurosurveillance 20(40):30036CrossRef
17.
go back to reference Keating SM, Pilcher CD, Jain V et al (2017) HIV antibody level as a marker of HIV persistence and low level viral replication. J Infect Dis 216:72–81CrossRefPubMedPubMedCentral Keating SM, Pilcher CD, Jain V et al (2017) HIV antibody level as a marker of HIV persistence and low level viral replication. J Infect Dis 216:72–81CrossRefPubMedPubMedCentral
19.
go back to reference Manns A, Miley WJ, Wilks RJ et al (1999) Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 180(5):1487–1493CrossRefPubMed Manns A, Miley WJ, Wilks RJ et al (1999) Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 180(5):1487–1493CrossRefPubMed
20.
go back to reference Grebe E, Welte A, Hall J et al (2017) Infection staging and incidence surveillance applications of high dynamic range diagnostic immune-assay platforms. J Acquir Immune Defic Syndromes 76(5):547–555CrossRef Grebe E, Welte A, Hall J et al (2017) Infection staging and incidence surveillance applications of high dynamic range diagnostic immune-assay platforms. J Acquir Immune Defic Syndromes 76(5):547–555CrossRef
Metadata
Title
Discrimination between recent and non-recent HIV infections using routine diagnostic serological assays
Authors
Jaythoon Hassan
Joanne Moran
Gary Murphy
Olivia Mason
Jeff Connell
Cillian De Gascun
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 5/2019
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-019-00590-0

Other articles of this Issue 5/2019

Medical Microbiology and Immunology 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.